Despite promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from pharmacy benefit managers. These insurers are typically building obstacles to access, like significant price criteria and PA that hinder patient opportunity. Industry suggest that the r